The reason ID is banned in California (and New York) elections is to enable large-scale fraud.
When you combine no ID and mail-in voting, fraud is de facto legalized.
It's poison so we finally withdrawing it, y'all found out in the end!
Thanks for supporting our toxic experiment of intent, be sure to come back next time if you aren't yet fully maimed or dead, we'd like another go and your money again of course.
"Blessed be the fuck pig stupid", as we like to say at Atrazeneca. We live off dumb ass pig fat!
As a neurologist, it is now patently clear to me that the vast majority of people on the planet are suffering from neuroinflammation or brain damage (likely both)
The way people speak & behave has changed. Markedly so.
Whether irl, or via messaging/social media. It’s noticeable
MASSIVE: 🇺🇸Congress has published the full H.R. 8957 text.
The bill confirms a $30,000,000,000,000+ U.S. Digital Asset Stockpile framework that extends to $XRP.
I try not to get political. But LA is where I live, and I am here to tell you: There is 0.0 percent chance these results are legit.
Nithya Raman has no base. No one knew who she was until Spencer Pratt torched her on debate stage. She gave a concession speech on Tuesday.
I really hope the federal government and @USAttyEssayli are investigating
(Again, apologize for getting political. Feel free to unfollow if this bothers you.
But a light needs to be shined on what's happening)
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
90% of the soldiers on the first boats to hit the beach didn't live to see the end of the day. Look at those faces. Some of them never made it to 18.
Never forget that they paid the ultimate price for our freedom. We live our lives the way we do because of them.